Improving hematopoietic stem cell transplantation (HSCT)
We develop novel stem cell-based therapies for blood disorders.
Jaap Jan Boelens
Our research focuses on safer and more effective HSCT, and we’re also interested in HSCT in rare non-hematopoietic diseases, for example, lysosomal storage disease and epidermolysis bullosae (EB).
U-DANCE also focuses on the immune-reconstitution after allogeneic HSCT: pharmaco-kinetics and dynamics of ATG (anti-thymocyte globuline), which is given prior to HSCT and has impact on the immune-reconstitution. A good, predictive immune-reconstitution is of importance to predict the effect of the DC-vaccine.The UMC Utrecht is the national referral center for HSCT in Lysosomal Storage Diseases and Epidermolysis Bullosae (EB). Recently, the CCMO approved a study protocol for a cord blood stem cell therapy in EB (the first in Europe). This clinical study will start early 2014. Furthermore, we collaborate closely with the San Raffaele-Telethon Institute for gene therapy in lysosomal storage diseases and immune-deficiencies. We plan to bring this therapy to Utrecht.